



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/533,555	05/02/2005	Wei Xu	EX03-037C-US	9452
63572	7590	07/29/2008	EXAMINER	
MCDONNELL BOEHNEN HULBERT @ BERGHOFF LLP 300 SOUTH WACKER DRIVE SUITE 3100 CHICAGO, IL 60606			MABRY, JOHN	
ART UNIT	PAPER NUMBER		1625	
MAIL DATE	DELIVERY MODE			
07/29/2008	PAPER			

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/533,555	Applicant(s) XU ET AL.
	Examiner John Mabry, PhD	Art Unit 1625

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 05 May 2008.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-9, 12-19, 24 and 27-38 is/are pending in the application.
 - 4a) Of the above claim(s) 24-30 is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-9, 12-19 and 31-38 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.


Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO/SB/06)
Paper No(s)/Mail Date 5/20/05, 6/20/05
- 4) Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) Notice of Informal Patent Application
- 6) Other: _____

DETAILED ACTION

Examiner's Response

Applicant's response on May 5, 2008 filed in response to the Election/Restriction dated February 4, 2008 has been received and duly noted. The Examiner acknowledges Applicants' election of Group II with traverse. The Applicant requested that Groups I-VIII be examined together. The Applicant alleges that the Examiner improperly restricted the instant application. Applicant points out the Tang reference (US 6,689,806) that the Examiner used to break the unity of invention does not fall within the scope of Applicant's Formula I. Examiner does not agree to this allegation. According to Applicant's Formula I of instant application and definitions therein, Tang discloses compound of Formula I wherein W=CR1 where R1=H, K=O, R2=H, X=phenyl and substituted pyrrole where L=NH, Q=CH and R5=CH3.



Tang et al (US 6,316,429 B1) discloses structural similar compounds of Formula I and teaches (L=S) and (L and Q=N) (see below and column 6).



It would be obvious to combine the references of US '806 and '429 to achieve the instant claimed invention.

Examiner has rejoined and examined Groups I-III. Examiner's Election/Restriction was properly restricted and Groups IV-VIII were not considered in this Office Action.

Thus, the restriction requirement is deemed proper and FINAL.

In view of this response, the status of the rejections/objections of record is as follows:

Applicant is respectfully reminded that it is required that all claims be amended to elected group. Examiner also warns Applicant not to introduce new matter when amending.

Specification Objections

The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed. The current title is "Kinase Modulators". Examiner suggests a title that directed towards elected group.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-9, 12-19 and 31-38 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for R13 being H, alkoxy, amino, alkylamino and heteroalicyclic where heteroalicyclic compounds are morpholino, pyrrolidinyl and piperidinyl; R4 and R5 fused to form phenyl; and R10 being H, alkyl,

alkoxy, cyano, halo, haloalkyl does not reasonably provide enablement for R13 being all claimed heteroalicyclic compounds, R4 and R5 being all fused cyclic rings claimed and R10 being all substituents as claimed.

The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims. The Specification does not provide any support for said variables at R13, R10 and R4/R5 positions. Pages 65-78 of the Specification describe starting materials and methods for synthesis of compounds as described above, but does not describe or list any reagents wherein compounds can be used to synthesis compounds where R13, R10 and R4/R5 positions as listed above.

Pursuant to *In re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988), one considers the following factors to determine whether undue experimentation is required: (A) The breadth of the claims; (B) The nature of the invention; (C) The state of the prior art; (D) The level of one of ordinary skill; (E) The level of predictability in the art; (F) The amount of direction provided by the inventor; (G) The existence of working examples; and (H) The quantity of experimentation needed to make or use the invention based on the content of the disclosure. Some experimentation is not fatal; the issue is whether the amount of experimentation is "undue"; see *In re Vaeck*, 20 USPQ2d 1438, 1444.

The analysis is as follows:

(1) Breadth of claims: Scope of the compounds. Owing to the range of many variables, millions of highly substituted indolin-2-one compounds are embraced.

(2) The nature of the invention: The invention is a highly substituted indolin-2-one compounds.

(3) Level of predictability in the art: It is well established that "the scope of enablement varies inversely with the degree of unpredictability of the factors involved," and chemical reactivity (which is affected by determinants such as substituent effects, steric effects, bonding, molecular geometry, etc) is generally considered to be an unpredictable factor. See *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970).

(4) Direction or Guidance: That provided is very limited. Applicant shows a general synthesis of compounds of application's general formula I. Pages 65-78 of the Specification describes starting materials and methods for synthesis of compounds wherein R13, R10 and R4/R5 positions, but does not describe or list any reagents wherein compounds can be used to synthesis compounds where R13, R10 and R4/R5 positions as listed above. There is limited evidence in the Specification of the example compounds that only covers no or a small portion of the substituents claimed of formula I. Thus, there is no specific direction or guidance regarding said compounds specifically mentioned in Scope.

The availability of the starting material that is needed to prepare the invention as claimed is at issue here...As per MPEP 2164.01 (b). A key issue that can arise when determining whether the specification is enabling is whether the starting materials or apparatus necessary to a make the invention are available. In the biotechnical area, this is often true when the product or process requires a particular strain of microorganism and when the microorganism is available only after extensive screening. The Court in *re Ghiron*, 442 F.2d 985, 991, 169 USPQ 723, 727 (CCPA 1971), made it clear that if the practice of a method requires a particular apparatus, the application must provide a sufficient disclosure of the apparatus if the apparatus is not readily available. The same can be said if certain chemicals are required to make a compound or practice a chemical process. *In re Howarth*, 654 F.2d 103, 105, 210 USPQ 689, 691 (CCPA 1981).

(5) State of the Prior Art: These compounds are substituted indolin-2-one compounds wherein R13 being H, alkoxy, amino, alkylamino and heteroalicyclic where heteroalicyclic compounds are morpholino, pyrrolidinyl and piperidinyl; R4 and R5 fused to form phenyl; and R10 being H, alkyl, alkoxy, cyano, halo, haloalkyl. So far as the examiner is aware, no substituted indolin-2-one compounds of general formula I wherein R1 equals all claimed heteroalicyclic compounds, R4 and R5 being all fused cyclic rings claimed and R10 being all substituents as claimed have been made or used.

It is not trivial to experimentally interchange any and all of the many substituents that exist. As described by F. Zaragoza Dörwald, most organic syntheses fail initially and chemical research is highly inefficient due to chemists spending most of their time "finding out what went wrong and why". Therefore, most syntheses of organic compounds are labor-intensive and demanding. Additionally, most final synthetic routes to desired organic molecules are usually very different from initially planned routes. A highly skilled chemist can agree that for many successful organic compounds made, many failures are encountered and experimental repetition is common. This also contributes to the burden and unpredictability of the syntheses of said compounds. (see "Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design" 2005 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

(6) Working Examples: Applicant shows examples (Table 2 on pages 54-63) but no working examples were shown wherein R13, R10 and R4/R5 positions equal aforementioned substituents and chemical moieties have been made or used of any kind.

(7) Skill of those in the art: The ordinary artisan is highly skilled, e.g. a masters or PhD level chemist.

(8) The quantity of experimentation needed: Since there are very limited working examples as described above, the amount of experimentation is expected to be high

and burdensome.

Due to the level of unpredictability in the art, the very limited guidance provided, and the lack of working examples, the Applicant has shown lack of enablement for the groups noted.

MPEP 2164.01(a) states, "A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. *In re Wright*, 999 F.2d 1557, 1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993)." That conclusion is clearly justified here.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:


(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.


Claims 1-9, 12-19 and 31-38 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tang (US 6,689,806) in view of Tang (US 6,316,429 B1) (PTO-1449) and in further view of US 6,569,868 (PTO-1449).

The instant application discloses compounds and pharmaceutical compositions of Formula I as disclosed below wherein R10=OCH₃, R5=H, R6=CH₃ and R12=CH₃ and R13=H.



Scope & Content of Prior Art MPEP 2141.01


Tang (US 6,689,806) compounds and pharmaceutical compositions of Formula I as disclosed below wherein R10=OCH₃, R5=H and R6=CH₃.



Tang et al (US 6,316,429 B1) discloses structural similar compounds of Formula I and teaches (Q=CH) and (L=N) (see below and column 6).




Tang (US '429) teaches the indole ring can be substituted with:



This teaching is found in column 5, lines 38-49 where R4 of US '429 can be -NR10R11 wherein R10 = H and R11 = piperidinyl substituted with alkyl.

Differences between Prior Art & the Claims MPEP 2141.02

US '806 differs from instant application at: (a) the 5-membered N containing



heteroaryl compound: which are positional isomers

and (b) the phenyl substitution on the indole ring in which there is a clear teaching as described above.

(a) There is little difference between the imidazole being bonded to the 4-position as compared at the 2-position on the claimed structure of formula I. It is well established that position isomers are *prima facie* structurally obvious even in the absence of a teaching to modify. The isomer is expected to be prepared by the same

method and to have generally the same properties. This expectation is then deemed the motivation for preparing the position isomers. This circumstance has arisen many times. See: *Ex parte Englehardt*, 208 USPQ 343, 349; *In re Mehta*, 146 USPQ 284, 287; *In re Surrey*, 138 USPQ 67; *Ex Parte Ulliyot*, 103 USPQ 185; *In re Norris*, 84 USPQ 459; *Ex. Parte Naito*, 168 USPQ 437, 439; *Ex parte Allais*, 152 USPQ 66; *In re Wilder*, 166 USPQ 545, 548; *Ex parte Henkel*, 130 USPQ 474; *Ex parte Biel*, 124 USPQ 109; *In re Petrzilka*, 165 USPQ 327; *In re Crownse*, 150 USPQ 554; *In re Fouche*, 169 USPQ 431; *Ex parte Ruddy*, 121 USPQ 427; *In re Wiechert*, 152 USPQ 249, *In re Shetty*, 195 USPQ 753; *In re Jones*, 74 USPQ 152, 154. There may be others as well. Thus, said claims are rendered obvious by Tang et al.


For example, "Position isomerism has been used as a tool to obtain new and useful drugs" (*Englehardt*) and "Position isomerism is fact of close structural similarity" (*Mehta*, emphasis in the original). Note also *In re Jones*, 21 USPQ2d 1942, which states at 1943 "Particular types or categories of structural similarity without more, have, in past cases, given rise to *prima facie* obviousness"; one of those listed is "adjacent homologues and structural isomers". Position isomers are the basic form of close "structural isomers." Similar is *In re Schechter and LaForge*, 98 USPQ 144, 150, which states "a novel useful chemical compound which is homologous or isomeric with compounds of the prior art is unpatentable unless it possesses some unobvious or unexpected beneficial property not possessed by the prior art compounds." Note also *In re Deuel* 34 USPQ2d 1210, 1214 which states, "Structural relationships may provide the requisite motivation or suggestion to modify known compounds to obtain new

compounds...a known compound may suggest its analog or isomers, either geometric (cis v. trans) or position isomers (e.g. *ortho* v. *para*)." See also MPEP 2144.09, second paragraph. Further, the reference provides for the ring being substituted in any position.

Prima Facie Obviousness, Rational & Motivation MPEP 2142-2413

It would be obvious to combine the references of US '806 and '429 to achieve the instant claimed invention. An artisan of ordinary skill would be motivated to use (and obvious to try) US '806 which teaches the core of the claimed genus of Formula I and combine it with the teachings of US '429 in order to treat/modulate/inhibit the activity of a protein kinase as taught by both mentioned US patent references.

Additionally, US '806 teaches the phenyl ring substitution where R13-R16 can be NR25R26, wherein R25 is H and R26 is heteroaryl (see column 13).



or a physiologically acceptable salt or prodrug thereof where p is 0 or 1.

When p is 1, then M , Q , T , U and V are independently selected from the group consisting of carbon and nitrogen, it being understood that, when M , Q , T , U , or V is nitrogen, R_{20} , R_{21} , R_{22} , or R_{23} , respectively, do not exist.


When p is 0, then M , Q , U , and V are independently selected from the group consisting of carbon, nitrogen, oxygen and sulfur, it being understood that, when M , Q , U , or V is oxygen or sulfur or nitrogen (wherein said nitrogen is participating in a double bond), R_{20} , R_{21} , R_{22} , R_{23} , or R_{24} , respectively, do not exist.

R_{16} , R_{17} , R_{18} , R_{19} , R_{20} , R_{21} , R_{22} , R_{23} , or R_{24} are independently selected from the group consisting of hydrogen, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, 40 aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, mercapto, alkylthio, aryloxy, sulfanyl, sulfonyl, S-sulfonamido, N-sulfonamido, carbonyl, C-carboxy, O-carboxy, carboxyalkyl, cyano, nitro, halo, O-carbamyl, N-carbamyl, C-amido, N-amido and $-NR_{25}R_{26}$. 45

R_{20} and R_{21} or R_{21} and R_{22} or R_{22} and R_{23} or R_{23} and R_{24} may combine to form a five-member or a six-member aryl or heteroaryl ring.

R_{25} and R_{26} are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, 50 aryl, heteroaryl, carbonyl, sulfonyl, and, combined, a five-member or a six-member heteroalicyclic ring.

US 6,569,868 (PTO-1449) discloses species and teachings as claimed in the instant application (claims 1-9, 12-19 and 31-38). US '868 provides further support that compounds and teachings of similar structures of the instant invention are well known in the prior art.



The scope of this invention includes physiologically acceptable salts and products of the compounds claimed herein.

A, B, D and E are independently selected from the group consisting of carbon and nitrogen whereas it is understood that when A, B, D or E is nitrogen, R¹, R², R³ or R⁴, respectively, does not exist and there is no bond.

G and J are selected from the group consisting of nitrogen and carbon such that, when G is nitrogen, J is carbon and when J is nitrogen, G is carbon. When either G or J is nitrogen then R⁵ or R⁶, respectively, does not exist.

R² and the imidazolyl ring may exchange places on the double bond; i.e., compound 1 may exist in the E or Z configuration about the double bond at the 3-position of the 2-indolinone.

R¹ and R² are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, hydroxy, alkoxy, C-carboxy, O-carboxy, C-amido, C-thioamido, sulfonyl and trihalomethylsulfonyl.

R⁷ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl and halo.

R⁸, R⁹ and R¹⁰ are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclic, halo, trihalomethyl, hydroxy, alkoxy, aryloxy, C-carboxy, O-carboxy, carbonyl, nitro, cyano, S-sulfonamido, amino and $-\text{NR}^{11}\text{R}^{12}$.

R¹⁰ and R¹¹ are independently selected from the group consisting of alkyl, cycloalkyl, aryl, carbonyl, sulfonyl, trihalomethanesulfonyl and, combined, a five-member or a six-member heterocyclic ring.

R¹, R², R⁸ and R⁹ are independently selected from the group consisting of hydrogen, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclic, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thiosulfonyl, sulfonyl, S-sulfonamido, N-sulfonamido, N-trisulfonylmethanesulfonamido, carbonyl, C-carboxy, O-carboxy, cyano, nitro, halo, cyanoato, isocyanato, thiocyanato, isothiocyanato, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, amino and $-\text{NR}^{11}\text{R}^{12}$.

R⁶ and R⁷ or R⁷ and R⁸ or R⁸ and R⁹, combined, may form a five or six-membered aromatic, heteroaromatic, alicyclic or heterocyclic ring such as, by way of example and not limitation, a methylenedioxy or an ethylenedioxy ring.

The key to supporting any rejection under 35 U.S.C. 103 is the clear articulation of the reason(s) why the claimed invention would have been obvious. The Supreme Court in KSR noted that the analysis supporting a rejection under 35 U.S.C. 103 should be made explicit. The Court quoting *In re Kahn*, 441 F.3d 977, 988, 78 USPQ2d 1329, 1336 (Fed. Cir. 2006), stated that “[R]ejections on obviousness cannot be sustained by mere conclusory statements; instead, there must be some articulated reasoning with some rational underpinning to support the legal conclusion of obviousness.” KSR, 550 U.S. at ___, 82 USPQ2d at 1396. Exemplary rationales that may support a conclusion of obviousness include:

- (A) Combining prior art elements according to known methods to yield predictable results;
- (B) Simple substitution of one known element for another to obtain predictable results;
- (C) Use of known technique to improve similar devices (methods, or products) in the same way;
- (D) Applying a known technique to a known device (method, or product) ready for improvement to yield predictable results;
- (E) “Obvious to try” – choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success;
- (F) Known work in one field of endeavor may prompt variations of it for use in either the same field or a different one based on design incentives or other market forces if the variations are predictable to one of ordinary skill in the art;

(G) Some teaching, suggestion, or motivation in the prior art that would have led one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention. See MPEP § 2143 for a discussion of the rationales listed above along with examples illustrating how the cited rationales may be used to support a finding of obviousness. See also MPEP § 2144- §2144.09 for additional guidance regarding support for obviousness determinations.

The aforementioned reasons above describe rationales that support a conclusion of obviousness based upon the KSR International Co. v. Teleflex Inc. decision. Letters (A)-(G) rationale is supported above.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Conclusion

Applicant is respectfully reminded that it is required that all claims be amended to elected group. Examiner also warns Applicant not to introduce new matter when amending.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to John Mabry, PhD whose telephone number is (571) 270-1967. The examiner can normally be reached on M-F from 9am to 5pm.

If attempts to reach the examiner by telephone are unsuccessful, the Examiner's primary examiner can be reached at (571) 272-0684, first, or the Examiner's supervisor, Janet Andres, PhD, can be reached at (571) 272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

/John Mabry/
Examiner
Art Unit 1625

/Rita J. Desai/
Primary Examiner, Art Unit 1625